The chimeric protein Bcr/Abl has been connected to several signalling pathways such as AKT, JNK or ERK1/2. Here, we present evidence showing that Bcr/Abl is able to modulate the p38 MAPK pathway. Transient transfection experiments indicated that over-expression of Bcr/Abl in 293T is able to activate p38 MAPK or induce p73 stabilization, suggesting that c-Abl and Bcr/Abl share some biological substrates. Interestingly, the control exerted by Bcr/Abl on the p38 MAPK pathway was not only mediated by the tyrosine kinase activity of Bcr/Abl. In fact, Bcr alone is able to induce P38 MAPK activation specifically through MKK3. Supporting these observations Chronic Myeloid Leukaemia-derived K562 cells or BaF 3 cells stably transfected with Bcr/Abl showed higher levels of phosphorylated p38 MAPK compared to Bcr/Abl-negative cells. Interestingly, Bcr/Abl-negative cells activated p38 MAPK in response to Ara-C, while Bcr/Abl-positive cells were unable to activate p38 MAPK. Furthermore, inhibition of p38 MAPK activation by SKF860002 induces a resistant phenotype in Bcr/Abl negative cells. Our results demonstrate that the interference of Bcr/Abl in the p38 MAPK pathway is a key mechanism for explaining resistance to Ara-C in Bcr/abl positive cells.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.